Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada. J of Skin [Internet]. 2024 Jan. 16 [cited 2026 Apr. 19];8(1):s317. Available from: https://skin.dermsquared.com/skin/article/view/2397